Published in Amyotroph Lateral Scler on November 24, 2010
Neurological diseases and pain. Brain (2011) 1.01
A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int (2015) 0.93
Symptom Management and End-of-Life Care in Amyotrophic Lateral Sclerosis. Neurol Clin (2015) 0.85
The Relationship between Depressive Symptoms, Disease State, and Cognition in Amyotrophic Lateral Sclerosis. Front Psychol (2012) 0.81
Depression in amyotrophic lateral sclerosis. Neurology (2016) 0.81
Comorbidities in Neurology: Is adenosine the common link? Neuropharmacology (2015) 0.80
Effects of music and music therapy on mood in neurological patients. World J Psychiatry (2015) 0.80
Efficacy of hypnosis-based treatment in amyotrophic lateral sclerosis: a pilot study. Front Psychol (2012) 0.80
Diffusion tensor MRI changes in gray structures of the frontal-subcortical circuits in amyotrophic lateral sclerosis. Neurol Sci (2014) 0.78
Frontal assessment battery for detecting executive dysfunction in amyotrophic lateral sclerosis without dementia: a retrospective observational study. BMJ Open (2015) 0.77
Hypnosis-based psychodynamic treatment in ALS: a longitudinal study on patients and their caregivers. Front Psychol (2015) 0.77
Fatigue and Depression in Iranian Amyotrophic Lateral Sclerosis Patients in Tehran in 2012. Electron Physician (2016) 0.75
Frequency and risk factor analysis of cognitive and anxiety-depressive disorders in patients with amyotrophic lateral sclerosis/motor neuron disease. Neuropsychiatr Dis Treat (2015) 0.75
Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis. NeuroRehabilitation (2015) 0.75
Non-Motor Symptoms in Patients Suffering from Motor Neuron Diseases. Front Neurol (2016) 0.75
Association between depression and survival in Chinese amyotrophic lateral sclerosis patients. Neurol Sci (2016) 0.75
Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). J Neurol Neurophysiol (2017) 0.75
Depression and anxiety in a case series of amyotrophic lateral sclerosis: frequency and association with clinical features. Einstein (Sao Paulo) (2017) 0.75
The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. Arch Gen Psychiatry (1992) 21.60
Prevalence of depression by race/ethnicity: findings from the National Health and Nutrition Examination Survey III. Am J Public Health (2005) 3.23
Fatigue and depression are associated with poor quality of life in ALS. Neurology (2003) 2.49
Survival in amyotrophic lateral sclerosis. The role of psychological factors. Arch Neurol (1994) 2.02
Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres. On behalf of the Big Lung Trial Steering Committee. Thorax (2000) 1.84
Prevalence of depressive disorders and change over time in late-stage ALS. Neurology (2005) 1.80
Severity of depressive symptoms and quality of life in patients with amyotrophic lateral sclerosis. Neurorehabil Neural Repair (2005) 1.40
Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs (2007) 1.38
Clinical trial enrollers vs. nonenrollers: the Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Control Clin Trials (1996) 1.30
Correlates of suffering in amyotrophic lateral sclerosis. Neurology (1999) 1.21
A cross sectional study on determinants of quality of life in ALS. J Neurol Neurosurg Psychiatry (2004) 1.15
Validity of the ALS-Depression-Inventory (ADI-12)--a new screening instrument for depressive disorders in patients with amyotrophic lateral sclerosis. J Affect Disord (2008) 1.03
Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol (2007) 1.01
Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler (2008) 1.00
Assessment of depression in patients with motor neuron disease and other neurologically disabling illness. J Neurol Sci (1997) 0.97
Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2010) 2.91
Transcranial magnetic stimulation of the brain: guidelines for pain treatment research. Pain (2015) 2.11
Discovery and verification of amyotrophic lateral sclerosis biomarkers by proteomics. Muscle Nerve (2010) 1.48
Lithium therapy in ALS. Amyotroph Lateral Scler (2008) 1.45
Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol (2011) 1.27
Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann Neurol (2005) 1.11
Motor unit number estimation predicts disease onset and survival in a transgenic mouse model of amyotrophic lateral sclerosis. Muscle Nerve (2006) 1.04
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol (2013) 1.01
Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler (2008) 1.00
Pilot-testing an applied competency-based approach to health human resources planning. Health Policy Plan (2012) 0.98
ALS drug development: reflections from the past and a way forward. Neurotherapeutics (2008) 0.96
Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J Proteome Res (2010) 0.95
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler (2012) 0.95
Design of phase II ALS clinical trials. Amyotroph Lateral Scler (2008) 0.93
Biomarkers for amyotrophic lateral sclerosis. Expert Rev Mol Diagn (2006) 0.93
Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association. PLoS One (2013) 0.91
Arimoclomol: a potential therapy under development for ALS. Expert Opin Investig Drugs (2009) 0.89
Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS). Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.88
Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol (2009) 0.86
Being PRO-ACTive: What can a Clinical Trial Database Reveal About ALS? Neurotherapeutics (2015) 0.86
Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis. Curr Opin Neurol (2012) 0.84
Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery. PLoS One (2007) 0.83
Nerve stimulator versus ultrasound guidance for placement of popliteal catheters for foot and ankle surgery. J Clin Anesth (2012) 0.82
Therapy development for ALS: lessons learned and path forward. Amyotroph Lateral Scler (2008) 0.81
A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 0.81
Opportunities for improving therapy development in ALS. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.81
Disease burden in upper motor neuron syndromes: a survey of patient perspectives. J Clin Neuromuscul Dis (2014) 0.81
Proposed BioRepository platform solution for the ALS research community. Amyotroph Lateral Scler (2010) 0.80
7-T MRI of the spinal cord can detect lateral corticospinal tract abnormality in amyotrophic lateral sclerosis. Muscle Nerve (2013) 0.79
Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology (2013) 0.78
Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev Neurother (2006) 0.78
Thrombopoietin is ineffective in a mouse model of motor neuron disease. Amyotroph Lateral Scler (2008) 0.76
Seeking a measure of clinically meaningful change in ALS. Amyotroph Lateral Scler Frontotemporal Degener (2014) 0.76
Post-lumbar puncture headache is reduced with use of atraumatic needles in ALS. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.76
Is pentoxifylline safe and effective in patients with amyotrophic lateral sclerosis? Nat Clin Pract Neurol (2006) 0.75
Research to Action: an evaluation. Nurs Leadersh (Tor Ont) (2012) 0.75
The O/OREOS mission: first science data from the space environment viability of organics (SEVO) payload. Astrobiology (2012) 0.75
Vanadium, aluminum, magnesium and manganese are not elevated in hair samples in amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 0.75